



CRM TRIAL CONNECT 2026

NEWSLETTER

MAY 2026

PRE-CONFERENCE



NPRA Good Submission Practice Workshop (FIH)

For First-in-Human trials, every submission begins with one priority: safety. The NPRA Good Submission Practice Workshop gave participants a practical look into what it takes to prepare stronger CTIL/CTX submissions for early-phase studies, from inspection readiness under the NPRA Phase 1 Accreditation Programme to the investigator's responsibility in protecting trial participants. Led by speakers from Sarawak General Hospital and NPRA, the session also guided participants through FIH CTIL submission requirements, common regulatory questions and case study discussions, offering useful takeaways to improve dossier quality and support safer, more prepared First-in-Human research in Malaysia.



Oncology Workshop

Clinical Research Malaysia (CRM) and ATLAS joined forces for a two-day Oncology Workshop aimed at helping investigators shape stronger and more focused oncology research proposals. Guided by Dr Mitsumi Terada from the National Cancer Center Japan, the workshop brought together oncology researchers, ATLAS faculty members and industry experts from Malaysia and the region for practical discussions on clinical trial management, investigator-initiated trials, innovative trial designs and biostatistics. Through group discussions and proposal review sessions, participants gained valuable feedback to sharpen their study design, strengthen statistical planning and improve overall proposal quality, while encouraging greater collaboration in advancing oncology clinical research.





MAY 2026

AFFORDABLE THERAPEUTICS WORKSHOP



**INTERNATIONAL AFFORDABLE
 DIAGNOSTICS AND
 THERAPEUTICS ALLIANCE**



How can existing medicines be repurposed to make treatments more accessible and affordable? The IA-DATA Affordable Therapeutics Workshop brought together researchers, clinicians, regulators and industry experts to explore practical solutions for advancing drug repurposing in Malaysia and the ASEAN region. Discussions covered areas ranging from clinical trial design and regulatory pathways to the use of AI and in-silico tools in research, while interactive sessions encouraged participants to exchange ideas, refine concepts and strengthen future regional collaboration in therapeutic development.

PRE-CONFERENCE



ATLAS BOARD MEETING



The ATLAS Board Meeting was held during the CRM Trial Connect 2026 pre-conference programme, bringing regional oncology experts within the network together to share research updates and discuss future collaboration. The meeting focused on ongoing ATLAS study groups, investigator-initiated research and collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).



MAY 2026

PRE-CONFERENCE

AFFORDABLE DIAGNOSTICS WORKSHOP



INTERNATIONAL AFFORDABLE DIAGNOSTICS AND THERAPEUTICS ALLIANCE



Innovation and accessibility were at the centre of discussions during the IA-DATA Affordable Diagnostics Workshop, where researchers and healthcare experts explored the future of diagnostics in infectious disease management. Through discussions on clinical applications, regulatory pathways and collaborative development strategies, the workshop encouraged new ideas and partnerships to strengthen diagnostic innovation in Malaysia and the ASEAN region.



PMDA-ATC

PMDA-ATC AND CRM CLINICAL TRIAL AND GCP WORKSHOP



The PMDA-ATC & CRM Clinical Trial and GCP Workshop created a focused platform for regulators and clinical research experts to exchange insights on clinical trial oversight, GCP inspection practices and evolving developments in the research landscape. Through country updates and shared experiences, the workshop encouraged practical knowledge exchange while strengthening regional collaboration towards higher quality and compliance in clinical research.



MAY 2026

PRE-CONFERENCE

BUILDING STRONGER READINESS FOR EARLY PHASE CLINICAL TRIALS

The Early Phase Training in Collaboration with Peter MacCallum Cancer Centre brought together Study Coordinators and Clinical Trial Assistants (CTAs) from across the Northern, Central, Southern, East Coast and East Malaysia regions for a focused learning experience on early phase clinical trials.

Conducted by Marian Lieschke, Helen Stevens and Felicity McLeay from Peter MacCallum Cancer Centre — Australia’s largest cancer centre and one of the leading oncology institutions in the Southern Hemisphere — the programme offered practical insights into the demands and responsibilities involved in Phase 1 trial delivery.

As early phase studies continue to shape the future of clinical innovation, participants strengthened their understanding of patient safety oversight, protocol compliance, data integrity and overall site readiness, all of which are essential in supporting safe and high-quality clinical trial conduct.

Beyond technical learning, the training also created opportunities for collaboration and knowledge-sharing across regions, reinforcing the importance of consistency, preparedness and operational excellence within the clinical research landscape.





MAY 2026

PRE-CONFERENCE

EQUIPPING TEAMS FOR BETTER CLINICAL RESEARCH DELIVERY

Behind every successful clinical trial is a team that can adapt quickly, communicate clearly and uphold quality with confidence. A series of training sessions brought these essential skills into focus, equipping CRM Study Coordinators (SCs) and Clinical Trial Assistants (CTAs) with practical tools to navigate the fast-moving realities of clinical research.

The session ‘SC as the Quality Owner’, led by Ms Adeline from Syneos Health, encouraged a shift in perspective on the role of SCs within site operations. More than supporting protocol procedures, participants explored how SCs play an important role in maintaining quality, identifying risks early and safeguarding patient safety throughout the research process.

Adding a more people-focused dimension, ‘Time for Productivity’ by Coach Michael Kim explored how communication, adaptability and emotional awareness can influence performance in high-pressure environments. Through practical and engaging discussions, participants reflected on how to communicate more confidently, respond constructively to challenges and work more effectively within teams.

The momentum continued with ‘Communicate for Results’, a session focused on sharpening communication techniques and improving collaboration across clinical research settings. Participants gained insights into clearer message delivery, stronger stakeholder engagement and more effective teamwork in increasingly dynamic environments.

Together, the sessions reinforced a simple but important message — strong clinical research is not built on systems alone, but on people who are prepared, adaptable and committed to continuous improvement.



CRM TRIAL CONNECT 2026



MAY 2026



A BIGGER STEP FORWARD FOR CRM TRIAL CONNECT 2026

CRM Trial Connect 2026 officially opened with more than 1,200 participants gathering for what has become one of the region's growing platforms for clinical research collaboration and knowledge-sharing. Officiated by Health Minister Datuk Seri Dr Dzulkefly Ahmad, this year's conference featured 25 sessions and tracks, including pre-conference programmes covering key developments in clinical research, innovation and regulatory practices. The event also placed stronger emphasis on patient-centric engagement through dedicated forums and discussions, reflecting the growing importance of patient voices in shaping the future of clinical research.





MAY 2026

CRM TRIAL CONNECT 2026

CELEBRATING EXCELLENCE IN CLINICAL RESEARCH



The CRM Sponsored Research Awards (SRA) 2026 recognised the people and organisations driving Malaysia’s clinical research ecosystem forward, from investigators and study sites to industry partners and scientific publications. Presented during CRM Trial Connect 2026, the awards highlighted outstanding contributions, collaboration and innovation that continue to strengthen sponsored research and elevate Malaysia’s presence in the global clinical research landscape.



**Investigator of the Year:
 Dr Voon Pei Jye**



**Study Site of the Year (Overall):
 University Malaya Medical Centre**



**Sponsor of the Year:
 AstraZeneca**



**Study Site of the Year (MOH):
 Sarawak General Hospital**



**CRO of the Year:
 IQVIA**



**Publication of the Year:
 IQVIA**

CRM TRIAL CONNECT 2026



MAY 2026



STRENGTHENING RESEARCH PARTNERSHIPS

The Opening Ceremony also marked two important collaborations aimed at widening Malaysia's clinical research network. Through the MoU exchange with Monash Health and Collaborative Research Agreement exchange with ATLAS, CRM continues to build meaningful partnerships that support knowledge-sharing, research growth and stronger international collaboration.



CELEBRATING CLINICAL TRIALS DAY



CRM Trial Connect 2026 marked Clinical Trials Day with a meaningful celebration officiated by Health Minister Datuk Seri Dr Dzulkefly Ahmad. Observed globally on May 20, the occasion served as a timely reminder of the vital role played by researchers, healthcare professionals, industry partners and trial participants in advancing medical progress and improving patient care.



CRM TRIAL CONNECT 2026



MAY 2026



PATIENT ENGAGEMENT FORUM

Held in conjunction with the celebration, the Patient Engagement Forum placed the patient voice at the centre of clinical research conversations. Moderated by Dr Diana Foo, the forum featured Dr Stephanie Tan, Ms Qusya Basher, Mr Edward Tan and Dr Pooja Sharma, who shared perspectives on the human side of clinical trials, from lived experiences and caregiver support to trust, communication and inclusivity in research.



THE OPENING EXCHANGE: APAC AS THE GLOBAL CO-ANCHOR FOR CLINICAL RESEARCH

What will it take for Asia-Pacific to become a stronger force in global clinical research? Moderated by Dr Abdullahi Sherif, the opening forum at CRM Trial Connect 2026 brought together Dr Sun Hualong, Dr Yasuhiro Fujiwara, Dr Joonwoo Bahn and Assoc Prof Tam C. Nguyen to discuss the opportunities, partnerships and infrastructure needed to strengthen APAC's role in shaping the next chapter of multinational clinical trials.



From regulatory alignment and cross-border collaboration to research readiness and innovation, the session opened meaningful conversations on how the region can move beyond participation and play a more active role in driving global clinical research forward.

CRM TRIAL CONNECT 2026



MAY 2026

TRANSLATING INNOVATION INTO EARLY-PHASE ONCOLOGY TRIALS

Globally recognised oncologist and physician-scientist Dr Timothy A. Yap shared insights into the rapidly evolving future of precision oncology and early-phase clinical trials, highlighting how biomarker-driven approaches, stronger trial design and greater research readiness are accelerating the development of more personalised cancer treatments.

Building on the discussion, Prof Cheong Sok Ching, Chief Scientific Officer of Cancer Research Malaysia, explored the growing importance of investigator-initiated discovery in driving meaningful breakthroughs in cancer research, while Dr Voon Pei Jye of Sarawak General Hospital offered perspectives on Malaysia's evolving oncology landscape and the increasing role of clinical trials in improving patient care and treatment access.



CRM TRIAL CONNECT 2026

INDUSTRY SYMPOSIUMS SPOTLIGHT MALAYSIA'S GROWING ROLE IN GLOBAL CLINICAL DEVELOPMENT



MAY 2026



The Industry Symposia at CRM Trial Connect 2026 brought together leading voices from global pharmaceutical companies, CROs and healthcare organisations to explore how Malaysia and Southeast Asia can strengthen their role in the future of global clinical development.

Led by the conference's Platinum Sponsors, the session featured discussions on evolving research pipelines, stronger site capabilities, operational readiness and the importance of strategic collaboration across the clinical trial ecosystem.

Speakers from Novo Nordisk, Novartis, Boehringer Ingelheim, DNDi and iNGENU CRO shared perspectives on how the region can move beyond trial participation to become a more active and trusted partner in global clinical research.

The symposium also highlighted the growing importance of site excellence, innovation and regional partnerships in attracting multinational clinical trials and expanding access to healthcare advancements across Southeast Asia.

Complementing the presentations, the forum titled Malaysia & Southeast Asia: Building a Collaborative Future in Global Clinical Trials, moderated by AstraZeneca Malaysia's Ms Tia Chen, reinforced the value of collaboration, shared expertise and long-term partnerships in shaping a stronger and more connected research ecosystem.

CRM TRIAL CONNECT 2026



MAY 2026



ATLAS TRACK HIGHLIGHTS REGIONAL COLLABORATION IN ASIA'S CLINICAL TRIAL LANDSCAPE

The ATLAS Track at CRM Trial Connect 2026 placed regional collaboration at the heart of Asia's growing clinical trial ambitions, reflecting the region's increasing momentum in shaping the future of multinational cancer research.

Chaired by Clinical Research Malaysia CEO Dr Akhmal Yusof, the session featured Dr Mitsumi Terada from the National Cancer Center Hospital, Japan, who shared updates on ATLAS' ongoing efforts to strengthen multinational clinical trials and deepen research partnerships across Asia.

The track also explored how emerging technologies such as artificial intelligence and advanced diagnostics could shape the future of clinical trials, with insights from Dr Kenichi Nakamura, Project Leader of the Asian Clinical Trials Network for Cancers. Bringing together oncology and clinical trial experts from Malaysia, Japan, Singapore and Taiwan, the session highlighted the importance of stronger regional collaboration, shared expertise and cross-border partnerships in advancing cancer research and strengthening Asia's role in the global clinical trial landscape.

CRM TRIAL CONNECT 2026

TRANSFORMING SITE MANAGEMENT IN CLINICAL RESEARCH PUTS THE SPOTLIGHT ON TRIAL DELIVERY



MAY 2026

Behind every successful clinical trial is a site team working through timelines, documentation, patient coordination and the many moving parts that keep a study on track.

The Transforming Site Management in Clinical Research session at CRM Trial Connect 2026 explored the operational backbone of clinical research, focusing on how sites can run trials more efficiently, consistently and sustainably.

Chaired by Ms Jessica Tan from IQVIA RDS Malaysia, the forum moved beyond theory to examine the real work behind trial delivery, from building momentum and coordinating research at scale to managing high study volumes without losing quality.

The session also reflected on the maturity of established trial sites, where strong systems, trained teams and steady processes help complex studies appear seamless from the outside.

Rather than presenting site management as a behind-the-scenes function, the forum positioned it as a key driver of research quality, patient experience and sponsor confidence.

It reinforced a clear message: clinical trials do not succeed by chance.

They succeed when sites are prepared, teams are supported and systems are strong enough to carry research from planning to patient impact.



CRM TRIAL CONNECT 2026

NCCR SYMPOSIUM HIGHLIGHTS RESEARCH AS A PATHWAY TO BETTER CARE

The NCCR Symposium at CRM Trial Connect 2026 looked at clinical research through a wider lens, focusing not only on scientific progress but also on how research can improve access to care.

Centred on the theme Clinical Research and Beyond: Unlocking Access to Care, the session explored the connection between research and development, public health needs, treatment affordability and primary care delivery.

The discussion brought attention to a key challenge in healthcare: innovation only becomes meaningful when patients can benefit from it in real life.

From translating research into public health action to addressing the cost of new treatments, the symposium encouraged a more practical view of clinical research as part of the broader healthcare system.

It also reflected the growing importance of bringing research closer to the community, especially through primary care, where early access, prevention and patient-centred care can make a lasting difference.

The session, overall reinforced that clinical research should not end with discovery, but continue towards access, affordability and better outcomes for patients.



MAY 2026



CRM TRIAL CONNECT 2026



MAY 2026



NAVIGATING THE REGULATORY FRONTIER

Bringing together representatives from MHRA, PMDA, NPRA and BPOM, the forum examined how regulators are responding to a changing research landscape shaped by innovation, complex trial designs and rising expectations for faster yet reliable approvals.

Chaired and moderated by Ms Li Ping Soo of AstraZeneca Malaysia, the session featured Prof Jacob George, Dr Shinichi Noda, Dr Zaryl Harza Zakaria and Ms Dra. Tri Asti Isnariani.

The discussions offered a broader view of how different regulatory agencies are strengthening their approaches to clinical trial oversight, investigational product evaluation, drug registration and safety.

The session also highlighted on the importance of stronger collaboration between regulators, industry and research stakeholders to support more efficient clinical trial development.



INTERNATIONAL AFFORDABLE
DIAGNOSTICS AND
THERAPEUTICS ALLIANCE

INTERNATIONAL AFFORDABLE DIAGNOSTICS AND THERAPEUTICS ALLIANCE TRACK

The IA-DATA Track brought fresh focus to a key healthcare challenge — making diagnostics and treatments more accessible to the people who need them. Through discussions on affordable diagnostics, drug repurposing and clinical research innovation, the track highlighted how collaboration can help turn promising ideas into practical healthcare solutions.




CRM TRIAL CONNECT 2026

EAST ASIA BIOTECH & PHARMA OUTLOOK OPENS NEW POSSIBILITIES FOR MALAYSIA'S CLINICAL RESEARCH GROWTH



MAY 2026



The East Asia Biotech & Pharma Outlook session at CRM Trial Connect 2026 offered an important look at how South Korea, Japan and China are driving the next phase of biotech, pharmaceutical innovation and clinical research in Asia.

Chaired by Dr Kan Yonemori from the National Cancer Center Hospital, the forum explored how stronger links between academia, hospitals, biotech companies and pharmaceutical players can turn research ideas into real treatment solutions.

The discussion moved across South Korea's academia-biotech-pharma progress, Japan's drug development landscape, China's fast-growing clinical research ecosystem, cell and gene therapy development, and the wider potential for East-Southeast Asia collaboration in clinical trials.

For Southeast Asia (SEA), these conversations matter deeply.

As the country works to strengthen its position as a regional clinical research hub, the forum offered valuable lessons on how mature research ecosystems are built through long-term investment, industry readiness, regulatory support and cross-border partnerships.

It also showed how SEA region can benefit from deeper regional collaboration, whether through access to more multinational trials, stronger knowledge exchange, better research capabilities or greater opportunities for local investigators and patients.

The session reinforced that the future of clinical research in Asia will not be built by one country alone.

By learning from East Asia's innovation engines and connecting more closely with regional partners, the region has the opportunity to play a stronger role in advancing clinical trials, improving patient access and supporting the growth of next-generation therapies.

CRM TRIAL CONNECT 2026



MAY 2026



RETHINKING INFECTIOUS DISEASE R&D FOR A MORE PREPARED FUTURE

As infectious diseases continue to evolve beyond borders, the session on Rethinking Infectious Disease R&D for Global Health Security brought timely conversations on how research, surveillance and regional cooperation must move hand in hand to strengthen future preparedness.

Chaired by Dr Daisuke Tokita and Dr Sifa Marie Joelle Muchanga from the Japan Institute for Health Security, the session gathered experts from academia, healthcare and industry to discuss the growing importance of stronger infectious disease clinical trial ecosystems across the Asia-Pacific region.

Discussions ranged from translating surveillance data into vaccine and drug development, to the challenges of conducting infectious disease trials and the need for closer regional networks and industry collaboration to support faster, more coordinated responses during future health crises.





CRM TRIAL CONNECT 2026

MAY 2026

BRIDGING PARTNERSHIPS SPOTLIGHTS THE POWER OF CONNECTED RESEARCH



Clinical research is no longer driven by individual studies alone, but by the strength of partnerships that connect institutions, researchers, funders and health systems.

Chaired by Prof Lim Soo Kun from University Malaya Medical Centre (UMMC), the forum covered infectious disease trials, diagnostic research, genomics, institutional partnerships and regional research funding.

The session reflected how effective clinical research depends on strong coordination between researchers, healthcare institutions, funders and wider health systems.

Discussions included multinational infectious disease trials, the CVENUS study on central vein stenosis screening, genomic research on liver disease severity in Malaysians and collaborative frameworks for clinical excellence.

The forum also featured Funding for Impact: SEA DREAM and the Future of Health Research in ASEAN, which addressed the role of sustainable funding, mentorship and regional support in advancing health research.

CRM TRIAL CONNECT 2026



MAY 2026



PUTTING PEOPLE AT THE HEART OF RESEARCH

From lived experiences to patient advocacy, the patient partnership forum created space for meaningful conversations on how community voices can shape the future of clinical research. Featuring Dr Stephanie Tan, Ms Diana Rose De Silva, Ms Nidhi Swarup and Dato' Dr Saunthari Somasundaram, the discussion explored how trust, inclusion and meaningful engagement can lead to research that better reflects patients' needs, realities and hopes.

ASEAN AT THE CROSSROADS : REPOSITIONING THE REGION FOR THE NEXT WAVE OF GLOBAL CLINICAL TRIALS



The future of clinical research may increasingly be shaped closer to home. Moderated by Ms Nurul Izzah Anwar, this high-level forum brought together Prof Jacob George, Dr Yasuhiro Fujiwara, Assoc Prof Danny Soon, Ms Indri Rooslamati, Ms Rosliza Lajis and Prof Dato' Dr Adeeba Kamarulzaman to discuss how ASEAN can move beyond being a trial destination and emerge as a region capable of driving innovation, strengthening partnerships and influencing the next phase of global clinical development.

CRM TRIAL CONNECT 2026



MAY 2026



RECOGNISING LEADERSHIP THAT INSPIRES CHANGE

The presentation of the CRM Leadership Award to Prof Dato' Dr Adeeba Kamarulzaman recognised not only her achievements in infectious disease research, but also her lasting impact on public health and clinical research leadership.

From pioneering harm reduction initiatives in Malaysia to leading global conversations through the International AIDS Society, Prof Adeeba's work reflects a strong commitment towards advancing equitable, evidence-driven healthcare.

Her contributions continue to inspire researchers, healthcare professionals and advocates both locally and internationally.

CLOSING WITH SHARED MOMENTUM



CRM Trial Connect 2026 concluded with closing remarks by Director-General of Health Datuk Dr Mahathar Abd Wahab, bringing the conference to a meaningful end after days of learning, dialogue and collaboration across the clinical research community. His remarks reflected the strong momentum built throughout the event, as researchers, healthcare professionals, regulators, industry partners and patient voices came together with a shared commitment to advance clinical research in Malaysia and beyond. The ceremony also featured the MoU exchange between CRM with ADVANCE-ID (represented by Prof David Paterson), marking another hopeful step towards stronger international partnerships, greater knowledge-sharing and a more connected research ecosystem for the future.



RECOGNITION & APPRECIATION

Behind the success of CRM Trial Connect 2026 was the collective dedication, professionalism and teamwork of the organising committee, site teams and the wider CRM workforce, whose efforts brought the conference to life seamlessly over four impactful days.

From coordinating 10 pre-conference sessions and three parallel conference tracks to managing delegates, speakers, logistics and on-site operations, every contribution played an important role in shaping a meaningful experience for more than 1,200 participants and 95 faculty members.

The smooth execution of the conference reflected the strong collaboration across teams working behind the scenes, from scientific programme and speaker management to sponsorships, finance, media coordination, delegate engagement and floor operations.

CRM Trial Connect 2026 Organising Committee

- **Asha Thanabalan - Overall Lead**
- **Intan Munirah Mohd Murad - Scientific Programme**
- **Nurul Atiqah Abd Rahman - Legal, On-site Interviewer**
- **Siti Khadijah Sakaria — Opening Ceremony, Scientific Programme and Design Coordination**
- **Cheng Shu Hui — Pre-conference Programme, Scientific Programme, Sponsored Delegates Management and Floor Manager**
- **Majdiah Othman — Pre-conference Coordination, Speaker Management and Floor Manager**
- **Nor Hafiza Johari — Scientific Programme and Pre-conference Coordination**
- **Nur Afiqah Mokhtar — Sponsorship and Promotion**
- **Komala Pannir Selvam — Opening Ceremony and F&B Coordination**
- **Nor Suhaila Mohd Najman — Speaker Management**
- **Saidatul Nisaa Shamshul Kamal — Opening Ceremony Coordination**
- **Nurul Asyikin Abdul Razak — Opening Ceremony Coordination**
- **Shakirin Kamaruzaman — Pre-conference Coordination**
- **Safiah Sabrina Hassan — Opening Ceremony Coordination**
- **Nurul Syifa Mazlan — Pre-conference Coordination**
- **Sarena Hasniza Shamshuddin — Finance Coordination**
- **Fi'la Nazzeha Mohd Zaini — Finance Coordination**
- **Siti Sufea Irdina Shikh Salehuddin — Media Coordination and Speech Preparation**
- **Nur Syazwina Idris — Program Book Development and Administrative Coordination**
- **Nur Izzati Syuhaidah Mohd Jiwa — Sponsored Delegates Coordination**
- **Nur Aziemah Ab. Ghani — Pre-conference Coordination**
- **Nur Syamimi Mohd Hasni — Pre-conference Coordination**
- **Koh Liew Eu — Pre-conference Coordination**

MAY 2026



MAY 2026

RECOGNITION & APPRECIATION

Special acknowledgements to:

- Ahmad Syarif Ibrahim — Opening Ceremony Support
- Puteri Nur Najwa Nor Azman — Floor Manager
- Rivisya Manickam — Floor Manager
- Syafiqah Hanani Mohd Shahidin — Floor Manager
- Izzah 'Atira Hisham — Floor Manager
- Nur Yasmin Muhammad Fauzi — Emcee
- Venoo Kuppusamy - Onsite Interviewer
- Conference Ushers

CRM also extends its sincere appreciation to all supporting staff, volunteers and workforce members whose commitment and willingness to go beyond their responsibilities contributed greatly to the overall success of the event.





MAY 2026

RECOGNITION & APPRECIATION

PLATINUM SPONSORS





MAY 2026

RECOGNITION & APPRECIATION

GOLD SPONSORS



PUSAT PERUBATAN
Medical Centre





MAY 2026

RECOGNITION & APPRECIATION

SILVER SPONSORS

Johnson & Johnson



CRM TRIAL CONNECT 2026



MAY 2026





1200+ Attendees

227 Organisations

28 Sponsors

20 Countries

Snapshot of CRM Trial Connect 2026 Participants



Follow us for updates on future programs

